Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Diabetes Mellitus, Type 2 1Dementia 1Cognitive Dysfunction 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 282Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × mazdutide × Lymphoid × Clear all
NCT07083154 2026-03-05

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3 Recruiting
420 enrolled
Lymphoid

Dementia, Diabetes Mellitus, Type 2, Lymphoma, Follicular, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡